DRKS00009744已完成不适用
AROMA - Impact of radioembolization of hepatic malignomas on distal not irradiated tumor tissue. - AROMA
Klinik und Poliklinik für Radiologie Klinikum der Universität München Campus Großhadern0 个研究点目标入组 64 人开始时间: 2016年3月4日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 64
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •hepatic metastatic colorectal carcinoma
- •male/female, 18+
- •Indication for radioembolization and HDR-brachytherapy in two sessions
- •informed consent
- •chemotherapy break for at least 2 weeks before inclusion
- •no corticosteroides for at least 2 weeks before inclusion
排除标准
- •life expectancy < 3 month
- •extrahepatic tumor manifestation
- •hepatic tumorload > 70%
- •chronic infections
- •contraindication for angiography, MRI contrast media, X-ray contrast media, MRI and CT
- •liver cirrhosis
- •condition after resection of the papilla vateri or DHC stenting
- •cardio vascular disease (NYHA III/IV)
- •thrombotic/embolic episodes (stroke)
- •severe hemorrhages within last 3 month
- •secondary malignoma within last 5 years
- •immune suppressive therapy or disease (e.g. condition after organ transplantation, HIV, corticosteroides)
- •autoimmune disease or inflammatory bowel disease
研究者
相似试验
已完成
2 期
Study of Y90-Radioembolization With Nivolumab in Asians With Hepatocellular CarcinomaHepatoCellular CarcinomaNCT03033446National Cancer Centre, Singapore40
已完成
2 期
Adjuvant hepatic Holmium-166-radioembolization in patients with unresectable liver metastases of neuroendocrine origin, who have been treated with Lutetium-177-dotatate; a single center, interventional, non-randomized, non-comparative, open label, phase II studylever- en galwegneoplasmata malgine en niet-gespecificeerdliver metastases of neuroendocrine tumor1001981510014713NL-OMON45045niversitair Medisch Centrum Utrecht48
已完成
不适用
Interest of Functional MRI (Magnetic Resonance Imagery) (in Patients Suffering From Hepatocellular Carcinoma and Treated With YttriumHepatocellular CarcinomaNCT02003339Center Eugene Marquis25
已完成
2 期
HEPAR Primary: Holmium-166-radioembolization in Hepatocellular Carcinoma PatientsHepatocellular Carcinoma Non-resectableHepatocellular CarcinomaNCT03379844UMC Utrecht30
已完成
不适用
Safety and Feasibility of Radioembolization Using Ho-166 in Patients With Unresectable Hepatocellular CarcinomaHepatocellular CarcinomaNCT05643391Erasme University Hospital20